Andrew Kraft to Proto-Oncogene Proteins c-bcl-2
This is a "connection" page, showing publications Andrew Kraft has written about Proto-Oncogene Proteins c-bcl-2.
Connection Strength
1.425
-
Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737. Cancer Res. 2012 Jan 01; 72(1):294-303.
Score: 0.359
-
ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem. 2008 Sep 05; 283(36):25003-13.
Score: 0.284
-
The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene. 2003 Aug 07; 22(32):4953-63.
Score: 0.202
-
Bax-induced apoptotic cell death. Proc Natl Acad Sci U S A. 2000 Jan 18; 97(2):529-31.
Score: 0.158
-
The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway. Oncogene. 1999 Jul 08; 18(27):4022-31.
Score: 0.152
-
The kinase domain of Jak2 mediates induction of bcl-2 and delays cell death in hematopoietic cells. J Biol Chem. 1997 May 09; 272(19):12350-8.
Score: 0.131
-
Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy. Cancer Biol Ther. 2007 Jul; 6(7):1067-73.
Score: 0.066
-
The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther. 2005 Mar; 4(3):443-9.
Score: 0.056
-
Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis. Cancer Biol Ther. 2006 Aug; 5(8):1015-21.
Score: 0.016